Batch Release Testing Under 21 CFR Part 111 — Required vs. Best Practice

The Regulation Leaves Room for Interpretation

21 CFR Part 111 — the Current Good Manufacturing Practice regulations for dietary supplements — establishes the framework for quality control in supplement manufacturing. It requires testing. It requires specifications. It requires documented procedures. What it does not do is specify exactly which tests must be performed on every batch of every product.

That flexibility is intentional. The regulation is designed to be risk-based and product-specific. But it creates a practical challenge: manufacturers must determine for themselves what testing is sufficient to demonstrate compliance, and that determination must be defensible to FDA inspectors.

This post clarifies what Part 111 actually requires for batch release testing, where the regulation gives manufacturers discretion, and what testing practices go beyond the minimum but are worth implementing for quality and liability reasons.

---

What 21 CFR Part 111 Actually Requires

Identity Testing of Every Component

Section 111.75(a)(1) requires that you test each component used in manufacturing to verify its identity. This is one of the few absolute requirements in Part 111 — there is no risk-based exception for identity testing of components. Every lot of every raw material must be tested for identity before use.

The regulation does not specify which identity test to use. It requires that you use a test that is “appropriate for the component.” For botanical ingredients, appropriate tests include HPTLC, DNA barcoding, and microscopic examination. For chemical ingredients, FTIR or HPLC may be appropriate. The choice of method should be documented in your raw material specification.

Testing to Verify Specifications Are Met

Section 111.75(a)(2) requires that you test a subset of components to verify that they meet specifications — but it allows you to rely on a supplier’s CoA for components other than identity, provided you meet certain conditions:

• You have established the reliability of the supplier’s CoA through periodic confirmation testing
• You document the basis for relying on the CoA
• You perform at least one test to verify the CoA results on a periodic basis

This is the “CoA reliance” provision. It allows manufacturers to reduce testing frequency for established, qualified suppliers — but it does not eliminate testing. The periodic confirmation testing must be documented and must actually be performed.

Finished Product Testing

Section 111.75(c) requires that you test the finished batch to determine whether it meets product specifications before releasing it for distribution. The regulation requires testing for:

• Identity of the dietary supplement
• Purity (freedom from contaminants)
• Strength (potency/concentration of dietary ingredients)
• Composition (correct ingredient amounts)

The specific tests used to demonstrate these attributes are not prescribed by the regulation — they must be defined in your product specifications and testing procedures.

Label Claim Verification

For products with quantitative label claims (e.g., “500 mg vitamin C per serving”), you must have data demonstrating that the finished product meets those claims. This typically requires HPLC or equivalent quantitative testing. The frequency of this testing should be defined in your quality plan.

---

Where Manufacturers Commonly Fall Short

In our experience supporting supplement manufacturers through FDA inspections and quality system reviews, the most common gaps in batch release programs are:

1. Identity testing treated as optional for “trusted” suppliers Part 111 does not allow you to skip identity testing based on supplier trust. Identity testing of every component lot is mandatory. A well-documented supplier qualification program reduces the scope of other testing — it does not eliminate identity testing.

2. CoA reliance without documented periodic confirmation Manufacturers who rely on supplier CoAs for component testing must document the basis for that reliance and perform periodic confirmation testing. “We trust this supplier” is not a documented basis. The periodic confirmation testing must be scheduled, performed, and recorded.

3. Finished product specifications that are too vague “Meets label claim” is not a specification. A specification must include a measurable parameter, a test method, and an acceptance criterion. “Vitamin C: 450–550 mg/serving by HPLC method QC-001” is a specification.

4. No testing for contaminants in finished product Part 111 requires testing for purity — freedom from contaminants. For most oral supplement products, this includes at minimum microbial limits testing and heavy metals testing. The specific contaminants tested should be appropriate to the product’s ingredient profile and manufacturing process.

5. Inadequate documentation of out-of-specification investigations When a batch fails a specification, Part 111 requires a documented investigation before the batch is rejected or reworked. Many manufacturers lack a formal OOS investigation procedure, which is a frequent FDA 483 observation.

---

Best Practice Beyond the Minimum

The following testing practices are not explicitly required by Part 111 but represent quality best practice and reduce risk:

Stability testing: Part 111 does not require stability testing, but it does require that expiration dates be supported by data. Without stability data, you cannot defensibly assign an expiration date. A minimum stability program — accelerated and real-time testing at defined intervals — is strongly recommended for any product with a label expiration date.

Dissolution/disintegration testing: For tablets and capsules, dissolution or disintegration testing confirms that the product will release its ingredients appropriately. USP <711> (Dissolution) and USP <701> (Disintegration) provide the relevant methods. This testing is not required by Part 111 but is relevant to bioavailability claims and is increasingly expected by sophisticated customers.

Pesticide residue screening: Not required by Part 111 for finished products, but relevant for botanical-based products. California Prop 65 and some international markets have specific pesticide limits. Including periodic pesticide screening in your program reduces regulatory exposure.

Uniformity testing: For solid oral forms, content uniformity testing (USP <905>) confirms that the active ingredient is evenly distributed across the batch. Not required by Part 111, but relevant to potency claims and customer confidence.

---

Building a Compliant Batch Release Procedure

A compliant batch release procedure under Part 111 should document:

1. The list of tests to be performed on each batch, with test methods and acceptance criteria
2. The sampling plan for each test (sample size, number of samples, sampling location)
3. The procedure for reviewing batch records before release
4. The authority level required to approve batch release
5. The procedure for handling out-of-specification results, including investigation requirements
6. The record retention requirements for batch release documentation

---

Practical Checklist: Batch Release Testing Under 21 CFR Part 111

• Identity test performed on every component lot before use — no exceptions
• CoA reliance documented with periodic confirmation testing schedule and records
• Finished product specification includes measurable parameters, test methods, and acceptance criteria for identity, purity, strength, and composition
• Finished product tested for microbial limits and heavy metals at minimum
• Label claims supported by quantitative testing data (HPLC or equivalent)
• Out-of-specification investigation procedure documented and followed for any failing result
• Batch release approval documented with authorized signature and date
• Stability data available to support expiration dates assigned to finished products
• Batch records retained per Part 111 requirements (minimum 1 year past expiration date or 2 years past manufacture date, whichever is longer)